Why the study?
What are the patient perspectives and experiences regarding the burden of vitamin K antagonist therapy in patients with atrial fibrillation or venous thromboembolism?
What are the patient perspectives and experiences regarding the burden of vitamin K antagonist therapy in patients with atrial fibrillation or venous thromboembolism?
Answers are grounded in this paper and cite their sources.
Patients with AF or VTE find VKA therapy burdensome due to monitoring and dietary restrictions but accept these limitations due to a perceived lack of alternatives.
AIM: Limitations of vitamin K antagonists (VKAs) include frequent monitoring, dietary restrictions and drug interactions. This study conducted an indepth exploration of perspectives of VKA therapy in respondents with atrial fibrillation or venous thromboembolism. METHODS: A total of 60 respondents, recruited from the UK, USA and Spain, were interviewed on their experiences and views of VKA therapy. Thematic analysis was conducted on the data. RESULTS: Although there were some differences between the countries and some small differences between atrial fibrillation and venous thromboembolism respondents, many respondents found various aspects of VKA to be burdensome, including the international normalized ratio monitoring and dietary considerations. CONCLUSION: Atrial fibrillation and venous thromboembolism respondents accept the limitations of VKAs and the adjustments to their lifestyles, but recognize a lack of alternative treatment.
No takes yet. Share an insight, caveat, or question.
Wild et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: